Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 111Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 13Breast Neoplasms 11Stomach Neoplasms 10Neoplasms 10Prostatic Neoplasms 9Pheochromocytoma 9Pancreatic Neoplasms 9Carcinoid Tumor 9Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Sarcoma 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Ovarian Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Rectal Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Gallbladder Neoplasms 4

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Lung Neuroendocrine Tumor × NET × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡